Loading
companiesCompany
Prestige Biopharma
Prestige Biopharma is a Singapore-based antibody company, listed in Korea, that makes biosimilars and is developing PBP1510, a first-in-class antibody against the pancreatic cancer protein PAUF.
Also called: Prestige BioPharma LimitedKRX:950210
Overview
Prestige Biopharma develops biosimilars, including trastuzumab (Tuznue) and bevacizumab candidates, and novel antibodies. PBP1510 (ulenistamab) neutralises pancreatic adenocarcinoma up-regulated factor (PAUF), a secreted protein that drives tumour growth and immune evasion; it has orphan designations in the United States and Europe and is in a phase 1/2a trial with gemcitabine in advanced pancreatic cancer. The company also develops PBP1710 against CTHRC1.
Headquarters
Singapore, SG
Scorecard
All companies#483of 1244 companies, score 5
- phase 1/2 +1
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Biotech · KRX:950210
Stage
Public
Website
Phase 2Monoclonal antibody
PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.
drugs
Phase 2Monoclonal antibody